JYNT — The Joint Corp.

Summary of The Joint Corp. Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Q4 2025 Performance:
  • Revenue from continuing operations increased by 3.1% to $15.2 million.
  • Consolidated adjusted EBITDA rose 7.8% to $3.6 million.
  • System-wide sales decreased by 3.9% to $140 million; comparable sales (comp sales) were down 3.8%.
  • Consolidated net income for Q4 was $1 million, compared to a loss of $5.8 million in 2024.
• Full Year 2025 Performance:
  • Revenue totaled $54.9 million, up from $52.2 million in 2024.
  • Adjusted EBITDA from consolidated operations increased 14% to $13 million.
  • System-wide sales were flat at $532 million, with comp sales declining 0.4%.

2. Strategic Updates and Business Highlights:

• The company is on track to complete its transformation initiative, Joint 2.0, by the end of 2026, focusing on becoming a pure-play franchisor.
• Refranchising efforts have reduced corporate-owned clinics from 135 to 48, with active negotiations ongoing to sell the remaining clinics.
• Marketing strategies have shifted to focus on chiropractic care for pain relief, with increased investment in national advertising and SEO improvements.
• The introduction of new pricing strategies is being tested, with early indications suggesting potential benefits from higher price points.

3. Forward Guidance and Outlook:

• For 2026, The Joint Corp. expects:
  • System-wide sales between $540 million and $552 million.
  • Comp sales to range from negative 3% to positive 3%.
  • Consolidated adjusted EBITDA between $12.5 million and $13.5 million.
• The company anticipates a lower clinic count at the end of 2026 due to ongoing refranchising efforts but believes this will strengthen the foundation for future growth.

4. Bad News, Challenges, or Points of Concern:

• Comp sales were lower than expected in Q4, primarily due to a decrease in new patient counts.
• The company continues to face challenges with new patient acquisition, which has been identified as the weakest component of active member growth.
• Although attrition rates improved slightly, the overall performance in attracting new patients remains a significant concern.
• The economic climate may impact patient spending, particularly as many patients fall within a specific income range that has been affected by macroeconomic conditions.

5. Notable Q&A Insights:

• Management acknowledged that while new patient flow has been weak, improvements in lead generation and conversion efforts are being implemented.
• The company is testing a three-tiered pricing strategy, with early results indicating that higher price increases are more effective.
• There is cautious optimism regarding comp sales improvement in the second half of 2026, supported by easier year-over-year comparisons and ongoing marketing initiatives.
• The transition to a national marketing strategy is expected to enhance brand awareness and patient acquisition, although it requires time to yield significant results.

Overall, The Joint Corp. is making progress in its transformation and refranchising efforts, but faces ongoing challenges in patient acquisition and comp sales performance.